Table 3

Relative risk of selected cancer incidence for female registered nurses according to weighted duration of exposure to antineoplastic agents (method 2), 1974-2000 (N = 56,213)1,2,3,4

Site (ICD-9 code)

Weighted duration of exposure5

Observed

RR

CI (95%)

p-value6


All cancers except

< 15 days

2905

1.00

0.452

non-melanoma skin

15 to < 60 days

150

1.11

0.94-1.30

≥ 60 days

44

1.00

0.74-1.35

top 2 categories combined

194

1.08

0.93-1.25

Colon (153,159)

< 15 days

225

1.00

0.710

15 to < 60 days

11

1.16

0.63-2.13

≥ 60 days

< 3

top 2 categories combined

13

0.99

0.56-1.74

Rectum (154)

< 15 days

116

1.00

0.037

15 to < 60 days

10

1.85

0.96-3.56

≥ 60 days

4

1.93

0.71-5.25

top 2 categories combined

14

1.87

1.07-3.29

Lung (162)

< 15 days

202

1.00

0.867

15 to < 60 days

11

1.24

0.67-2.28

≥ 60 days

3

0.83

0.27-2.61

top 2 categories combined

14

1.22

0.65-1.94

Melanoma (172)

< 15 days

191

1.00

0.400

15 to < 60 days

12

1.28

0.71-2.30

≥ 60 days

3

1.28

0.41-4.02

top 2 categories combined

15

1.28

0.75-2.18

Breast (174)

< 15 days

1199

1.00

0.267

15 to < 60 days

64

1.08

0.84-1.39

≥ 60 days

23

1.23

0.82-1.87

top 2 categories combined

87

1.12

0.89-1.39

Uterus (179-182)

< 15 days

290

1.00

0.696

15 to < 60 days

9

0.72

0.37-1.40

≥ 60 days

7

1.66

0.78-3.53

top 2 categories combined

16

0.95

0.57-1.59

Ovary (183)

< 15 days

144

1.00

0.209

15 to < 60 days

6

0.90

0.40-2.06

≥ 60 days

< 3

top 2 categories combined

6

0.68

0.30-1.55

Bladder - including in-situ (188)

< 15 days

78

1.00

0.394

15 to < 60 days

6

2.00

0.86-4.65

≥ 60 days

< 3

top 2 categories combined

7

1.67

0.76-3.67

Brain (191-192)

< 15 days

43

1.00

0.292

15 to < 60 days

3

1.76

0.54-5.80

≥ 60 days

< 3

1.88

0.26-13.87

top 2 categories combined

4

1.79

0.63-5.10

Thyroid (193)

< 15 days

82

1.00

0.408

15 to < 60 days

4

0.93

0.34-2.56

≥ 60 days

< 3

top 2 categories combined

4

0.74

0.27-2.05

Ill-defined (195)

< 15 days

81

1.00

0.181

15 to < 60 days

5

1.33

0.54-3.31

≥ 60 days

3

2.09

0.66-6.65

top 2 categories combined

8

1.54

0.74-3.21

Lymphatic & Hematopoietic

< 15 days

219

1.00

0.482

(200-208)

15 to < 60 days

9

0.93

0.47-1.82

≥ 60 days

< 3

top 2 categories combined

11

0.84

0.46-1.55

Non-Hodgkin Lymphoma

< 15 days

121

1.00

0.643

(200, 202)

15 to < 60 days

6

1.06

0.47-2.43

≥ 60 days

< 3

0.49

0.07-3.52

top 2 categories combined

7

0.91

0.42-1.96

Leukemia (204-208)

< 15 days

59

1.00

0.930

15 to < 60 days

< 3

≥ 60 days

< 3

top 2 categories combined

3

0.89

0.27 - 2.88


1 Based on Poisson regression using a 10-year lag.

2 Cancer with an incidence of less than 3 were excluded.

3 N for top 2 categories of antineoplastic drug exposure = 7,635.

4 Adjusted for age and calendar year.

5 A weighted duration of exposure of 15 days is equivalent to full-time work for one year (240 days) at a job considered unlikely to be exposed; a weighted duration of exposure of 60 days is equivalent to full-time work for one year at a job considered possibly exposed.

6 Significance of the trend, derived from chi-square analysis.

Ratner et al. BMC Nursing 2010 9:15   doi:10.1186/1472-6955-9-15

Open Data